Mutations in hepatitis C virus NS3 protease domain associated with resistance to specific protease inhibitors in antiviral therapy naïve patients
- 20 April 2010
- journal article
- Published by Springer Science and Business Media LLC in Archiv für die gesamte Virusforschung
- Vol. 155 (5), 807-811
- https://doi.org/10.1007/s00705-010-0642-z
Abstract
The prevalence of naturally occurring mutations in hepatitis C virus associated with resistance to protease inhibitors in chronically infected patients has not been reported in Brazil. The NS3 serine protease domain was sequenced in 114 therapy-naïve patients infected with subtype 1a (n = 48), 1b (n = 53), or 3a (n = 13). A V36L mutation was observed in 5.6% patients infected with subtype 1b and in all isolates of the 3a subtype, and a T54S mutation was detected in 4.1% of isolates of subtype 1a. In conclusion, the presence of variants carrying mutations associated with resistance to protease inhibitors in therapy-naïve patients may be important for future therapeutic strategies.Keywords
This publication has 25 references indexed in Scilit:
- In Vitro Activity and Preclinical Profile of TMC435350, a Potent Hepatitis C Virus Protease InhibitorAntimicrobial Agents and Chemotherapy, 2009
- Inhibition and Binding Kinetics of the Hepatitis C Virus NS3 Protease Inhibitor ITMN-191 Reveals Tight Binding and Slow Dissociative BehaviorBiochemistry, 2009
- Protease and polymerase inhibitors for the treatment of hepatitis CLiver International, 2009
- Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patientsHepatology, 2008
- Natural presence of substitution R155K within hepatitis C virus NS3 protease from a treatment-naïve chronically infected patientHepatology, 2008
- Molecular basis of telaprevir resistance due to V36 and T54 mutations in the NS3-4A protease of the hepatitis C virusGenome Biology, 2008
- Molecular biology of hepatitis C virusThe Esophagus, 2007
- Dynamic Hepatitis C Virus Genotypic and Phenotypic Changes in Patients Treated With the Protease Inhibitor TelaprevirGastroenterology, 2007
- Sensitivity of NS3 Serine Proteases from Hepatitis C Virus Genotypes 2 and 3 to the Inhibitor BILN 2061Journal of Virology, 2004
- The solution structure of the N-terminal proteinase domain of the hepatitis C virus (HCV) NS3 protein provides new insights into its activation and catalytic mechanismJournal of Molecular Biology, 1999